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1-sentence condensation of the paper:  
Population testing for BRCA mutations is cost-effective in Sephardi Jewish women aged over 
30 in UK and US populations.  
 
Shortened Title: 
Cost effectiveness of population BRCA1 testing in Sephardi Jewish women 
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ABSTRACT: 
Background 
Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost-
effective compared to family-history(FH) based testing in Ashkenazi Jewish(AJ) women. 
However, only one of the three AJ BRCA1/BRCA2 founder-mutations 
(185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 6174delT(c.5946delT)) is found in the 
Sephardi Jewish(SJ) population (185delAG(c.68_69delAG)) and the overall prevalence of 
BRCA mutations in the SJ population is accordingly lower (0.7% compared to 2.5% in the AJ 
population). Cost-effectiveness analyses of BRCA testing have not previously been 
performed at these lower BRCA prevalence levels seen in SJ. Here we present a cost-
effectiveness analysis for UK and US populations comparing population-testing with Clinical-
criteria/FH-based testing in SJ women.  
Methods 
A Markov model was built comparing the lifetime costs-&-effects of population-based 
BRCA1-testing with testing using FH-based clinical criteria in SJ women ≥30years. BRCA1-
carriers identified were offered MRI/mammograms and risk-reducing surgery. Costs are 
reported at 2015 prices. Outcomes include breast cancer(BC), ovarian cancer(OC) and 
excess deaths from heart disease. All costs-&-outcomes are discounted at 3.5%. The time 
horizon is life-time, and perspective is payer. The incremental-cost-effectiveness-ratio (ICER) 
per quality-adjusted life-year (QALY) was calculated. Parameter uncertainty was evaluated 
through one-way and probabilistic-sensitivity-analysis (PSA). 
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Results 
Population-testing resulted in gain in life-expectancy of 12months (QALY=1.00). The 
baseline discounted ICER for UK population-based testing =£67.04/QALY and for US 
population=$308.42/QALY. Results were robust in the one-way sensitivity analysis. The PSA 
showed 100% of simulations were cost-effective at £20,000/QALY UK and the 
$100,000/QALY US WTP thresholds. Scenario analysis showed, population-testing remains 
cost-effective in UK and US populations even if pre-menopausal oophorectomy does not 
reduce BC-risk or if hormone-replacement-therapy compliance is nil.  
Conclusion 
Population-based BRCA1- testing is highly cost-effective compared to clinical-criteria driven 
approach in SJ women. This supports changing the paradigm to population-based BRCA- 
testing in the Jewish population regardless of Ashkenazi/Sephardi ancestry. 
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Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women  
INTRODUCTION 
 
Genetic testing for BRCA1/BRCA2 mutations has conventionally been offered to affected 
individuals or those fulfilling strict clinical or family-history (FH) based criteria. However, 
using this FH-based approach results in over 50% of BRCA1/BRCA2 carriers being missed, as 
they do not meet the threshold for these clinical criteria.1, 2  The Genetic Cancer Prediction 
through Population Screening (GCaPPS) randomized trial (ISRCTN73338115), demonstrated 
population-based BRCA1/BRCA2 founder mutation testing (performed regardless of 
personal or family history of cancer) in women of Ashkenazi Jewish (AJ) descent, to be both 
cost-saving and more effective compared to FH-based testing3 providing strong supporting 
evidence for its adoption. UK and Israeli studies have shown that population-based 
BRCA1/BRCA2 testing in Ashkenazi Jews is feasible, acceptable, identifies more people at 
risk and does not cause detrimental psychological and quality-of-life consequences.1, 2, 4 The 
increasing availability and access to Next Generation Sequencing platforms and concomitant 
decreasing cost of genetic-testing5 has rendered large scale high throughput testing of 
populations both more affordable and technically feasible. Given the findings of the GCaPPS 
randomized control trial, and corroborating cohort studies, many have advocated for 
BRCA1/BRCA2 testing to be offered to the whole Jewish population, regardless of family 
history.  
AJ are descendants of Jews who emigrated from France, Germany, and Eastern Europe in 
1800s-1900s. Sephardi Jews (SJ) are descendants of Jews from Spain and Portugal 
(Sephardim) as well as, North Africa, Iraq and Morocco (Mizrachim). Around 25% of the 
Jewish population is not of Ashkenazi descent.6 Importantly, while three BRCA1/BRCA2 
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founder mutations (185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 
6174delT(c.5946delT)) have been described in AJ, only one of these 
(185delAG(c.68_69delAG)) is found in SJ.7-9 Hence, the mutation prevalence in much lower 
in SJ (0.5%-1%) 8, 9 compared to AJ (2.5%).2 Population-testing studies have been undertaken 
in the AJ population in the UK, Israel and Canada and show acceptability of this approach as 
well as the feasibility of providing this outside a hospital setting.2, 4, 10 While, evidence exists 
to support a shift towards population-based testing in the AJ community, this evidence 
cannot be used to reach the same conclusion for the whole Jewish community as 
corresponding data on cost-effectiveness are lacking for the Sephardi population with the 
lower prevalence of mutations. This highlights the need for a greater evidence base in the SJ 
population.  
A cost-effectiveness assessment is a vital tool used to evaluate the costs and benefits of 
different health interventions. This helps with the allocation of scarce resources within 
healthcare and assists with policy decision making.11 In this study we for the first time 
evaluate and report on the cost-effectiveness of population-based BRCA-testing in the SJ 
population.  
METHODS 
The lifetime costs and effects of BRCA1 testing were analyzed through a Markov model 
(Figure-1) comparing the current practice of Clinical criteria/FH testing to population testing 
of all SJ women ≥30 years for the BRCA1 SJ mutation.  Separate analyses were performed 
for UK and US populations. Other analytical models assume all events occur simultaneously 
in the same time sequence. However, with a disease such as cancer events are likely to 
occur over a period of time. A Markov model allows for this temporal element and permits 
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patients to move through mutually exclusive health states through a series of transition 
probabilities over a period of time. The Markov model assumes genetic counselling and 
genetic testing was undertaken in women fulfilling clinical testing criteria in the FH arm and 
in all women in the population-testing arm. Clinical criteria for testing includes: personal 
history of ovarian cancer (OC) at any age; first degree relative with OC (any age); first-
degree-relative with or personal history of breast cancer (BC) <50 years; first-degree-relative 
with or personal history of male breast cancer at any age.2 Testing positive for the BRCA1 
mutation resulted in women being offered a risk-reducing salpingo-oophorectomy (RRSO) 
which would lead to a reduction in their OC risk.12 To reduce their BC risk, women testing 
positive were offered MRI and mammography screening or a risk-reducing mastectomy 
(RRM).13  Pre-menopausal bilateral oophorectomy is associated with an increased risk in 
cardiovascular mortality, especially in women who do not take hormone-replacement-
therapy (HRT).14, 15 The increased cardiovascular risk (number needed to harm (NNH)=1:33) 
is integrated in the model and HRT is given to women till the age of 51 (menopause) if they 
have an RRSO, with HRT compliance assumed to be 80% (CI:76%,83%).16 Additionally, costs 
of bone health monitoring and HRT supplementation are included in the model. All costs 
and outcomes were discounted at a rate of 3.5% in line with the reference case guidelines 
published by the National Institute of Health and Care Excellence (NICE).17 BC risk is not 
affected by taking short-term HRT after RRSO.18 As a mortality benefit has not been shown 
with OC screening, it has been excluded from the model.18   
Probabilities 
The various probabilities used in the model are described in Table-1. 
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Costs 
Costs are reported at 2015 prices and where required have been converted using the 
Hospital and Community Health Service Index.19, 20 They are derived from the health 
system/payer perspectives. These are described in detail in Table-2. In line with NICE 
recommendations, future healthcare costs outside of those associated with OC/BC were not 
considered.17  
Life years 
Lifetime horizons extending to 83/82 years for the female UK/US populations were used to 
model the lifetime risks and consequences of BRCA-testing. General population life tables 
were obtained from the Office of National Statistics for the UK population and from 
Surveillance, Epidemiology, and End Results Program for the USA population. Specific SJ 
data are unavailable for these estimates. Hence, life time SJ risks and survival estimates are 
assumed to be the same as the rest of the general population. The mean age for BC/OC 
onset was 41/54 years for BRCA1 mutations in SJ women respectively.21, 22 The mean ages 
for sporadic BC and OC were 57/62 years and 63/63 years in the UK/US populations 
respectively.22-24 Probability of dying from background mortality was taken from the general 
UK and US populations in the absence of SJ distinct data.25 Statistically significant 
differences in survival have not been observed between BRCA1 genetic and sporadic BC 
cases.26, 27 28 No statistically significant difference in 10year survival rates have been found 
between BRCA1-OC and sporadic-OC either. 29 The average 10-year survival for BC is 
78.4%/84.6% and OC is 34.5%/34.2% in UK/US populations.29, 30 After ten years survival, the 
probability of death was assumed to be the same as the general population.  
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Quality adjusted life years (QALY) 
QALYs are a measure of health outcomes recommended by NICE for use in economic 
evaluations. It uses utility-weights which reflects the preference of an individual for a 
particular health state between 1, indicating perfect health, and 0, indicating death. Utility 
weights are multiplied by survival in life-years to produce the QALY measure.31 The 
following utility-scores were used for early, advanced, recurrent and end stages of BC: 0.71, 
0.65, 0.45 and 0.16 respectively and were obtained from NICE guidance.32 The following 
utility-scores were used for early, advanced, recurrent and end stages of OC: 0.81, 0.55, 0.61 
and 0.16 respectively.33 In addition, women may experience negative health effects from 
undertaking a RRM and RRSO. 34, 35 To account for this, utility-scores of 0.88(SD=0.22) for 
RRM and 0.95(SD=0.10) for RRSO were incorporated in the model.36 
Analysis 
The Markov model used to evaluate the costs and outcomes is illustrated in Figure-1. All 
analyses were conducted in TreeAge Pro 2016 (Williamson, Massachusetts). The costs of the 
population-testing arm were compared to the costs of the FH-based testing arm. The effects 
evaluated in both arms were evaluated in terms of total life-years and QALYs. The discount 
rate of 3.5% was used for both costs-&-effects, in line with the NICE reference case which 
acknowledges values for future costs and benefits are considered lower in value than in the 
present.37  The incremental cost-effectiveness ratio (ICER) was estimated by dividing the 
difference in cost between the two strategies (Population testing and Criteria/FH testing) by 
the difference in effect. ICER= (CostPopulation testing – CostCriteria/FH testing)/(QALYsPopulation testing 
– QALYsCriteria/FH testing). The ICER calculated was compared to the NICE cost-effectiveness 
willingness-to-pay (WTP) threshold (£20,000-£30,000/QALY) for UK analysis,38 and 
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$100,000/QALY WTP for US analysis39, 40 to assess the cost-effectiveness of population-
based BRCA1 founder-mutation testing in SJ women.  
The baseline ICER calculated includes the benefit in BC-risk reduction from undergoing a 
RRSO. However, this benefit has recently been questioned by a Dutch group.41 Therefore, 
scenario analyses were performed for comparing population-testing with FH-testing where 
no reduction in BC-risk occurred following RRSO. A further scenario explored the impact on 
the results where no HRT was offered. Additionally, as RRM and RRSO rates in Israeli Jews 
are reported to be lower than BRCA-carriers living in Europe/North America, a scenario 
analysis of lower RRM rate (13%) and lower RRSO rate (49%) was also evaluated.42  
The parameters used in the model have a certain degree of uncertainty associated with 
them. To explore the uncertainty of the model results, extensive sensitivity analysis was 
undertaken. One-way sensitivity analysis varies the estimate of one parameter at a time, 
keeping all other parameters at their baseline to assess the impact of that parameter on the 
ICER.  Probabilities and utility-scores were varied by their 95% confidence-intervals, whilst 
costs were altered by +/-30%.  One-way analysis provides information on which parameter 
has the largest impact on the ICER and therefore, highlights parameters of major 
significance which could be the focus of further research. However, parameters are most 
likely to vary together and not independently of each other and so probabilistic sensitivity 
analysis (PSA) was also conducted. In the PSA parameters were varied simultaneously 
according to their distributions for a total of 10,000 iterations to investigate joint 
uncertainty. Distributions were assigned according to the literature: probabilities and 
utilities were fitted with a beta distribution and costs with gamma distributions.43, 44 The 
results of the 10,000 iterations were plotted on a cost-effectiveness acceptability curve 
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which portrays the proportion of simulations that are cost-effective at differing WTP 
thresholds for each arm of the Markov model.  
RESULTS 
The discounted values for total cost, QALYs and life-years for both the population-based 
testing and the Clinical Criteria/FH-based testing approaches are given in Table-3. The 
results show population-testing in SJ is cost-effective compared to current practice of BRCA-
testing using FH-based clinical criteria in both UK and US populations. Baseline results   show 
population-testing extends average life expectancy by 12.19/12.17 months and has an ICER 
of £67.04/QALY and $308.42/QALY in UK and US populations respectively. This is 
significantly below the NICE threshold of £20,000/QALY and $100,000/QALY US WTP 
threshold indicating population-testing is highly cost-effective.  
One way sensitivity analysis was undertaken for all the probabilities, costs and utilities. 
Figure-2 and Figure-3 show the parameters that had the largest impact on the ICER in the 
UK and US one-way analysis respectively. The model was most sensitive overall to BRCA1 
mutation prevalence estimates in the Sephardi population and in FH-positive individuals. 
However, these results still remain cost-effective at much well below the £20,000-
£30,000/QALY and $100,000/QALY WTP thresholds. The PSA (Figure-4 and Figure-5) shows 
that 100% of the iterations are cost-effective for population-based testing at the 
£20,000/QALY and $100,000/QALY WTP thresholds, again reconfirming that this strategy is 
highly cost-effective.  
The model remains cost-effective for the various scenario analyses undertaken. If it is 
assumed there is no risk reduction in BC-risk following RRSO then the ICER becomes 
£67.69/QALY with 12.18 months gain in life expectancy in the UK and an ICER of 
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$311.25/QALY with 12.17 months gain in life expectancy in the US. If women decline or are 
unable to take HRT, then the ICER for population testing increases to £67.05/QALY and 
$308.48/QALY, with a gain in life expectancy of 12.18/12.17 months in the UK/US 
respectively. The model is not very sensitive to the parameter of HRT use and the PSA shows 
that at >99% simulations remain cost-effective at lower rates of use. A lower uptake of RRM 
at 13% and RRSO at 49% has been reported in the Jewish population.42 Assuming a lower 
uptake of both surgeries, the ICER increases to £67.81/QALY and $312.84/QALY in UK/US 
populations with 12.17 months gain in life expectancy in both populations. All three 
scenarios represent a slight increase from the baseline ICERs of £67.04 and $308.42 in the 
UK and US populations. However, all scenarios remain cost-effective and markedly below 
the NICE £20,000/QALY and US $100,000/QALY WTP thresholds. In addition, even if the cost 
of testing rises to $2000/test population testing remains cost-effective, with an ICER= 
$1798/QALY. 
DISCUSSION 
 
Population-based BRCA-testing in the SJ population is highly cost-effective compared with a 
clinical criteria /FH-based strategy with an ICER of £67.04/QALY and $308.42/QALY, well 
below the NICE £20,000-£30,000/QALY and US $100,000/QALY WTP thresholds respectively. 
That 100% of simulations are cost-effective (£20,000/QALY and $100,000/QALY WTP 
thresholds), despite uncertainty in model parameters, is highly reassuring. Whilst evidence 
exists on the cost-effectiveness of population-testing in other Jewish populations, notably 
the AJ population,3 the literature has been lacking for the SJ population. This report 
addresses this knowledge gap and finds population-testing for BRCA1 founder mutations in 
SJ women to also be highly cost-effective, resulting in 12 months estimated life expectancy 
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gained, over clinical criteria driven testing. Around 20% of the Jewish population is 
Sephardi.6 These findings coupled with our earlier analysis showing cost-effectiveness in the 
AJ population,3, 45 support population-based BRCA-testing in the entire Jewish population. 
This study has a number of advantages. The comparator used in this analysis is based on 
current practice and NICE/ published clinical guidelines for BRCA management. In addition, 
the analysis meets NICE guidelines on economic evaluations. QALYs have been used as the 
measure of health effects, and costs and outcomes are discounted at the recommended 
3.5% rate. The lifetime time-horizon used is advantageous in mapping the full costs and 
outcomes over the lifetime of female SJ and not just the costs and outcomes occurred at the 
point of intervention. Furthermore, the possible adverse effects of undertaking prophylactic 
RRM and/or RRSO are reflected in the utility-values assigned to the prophylactic surgeries. 
We also include a detriment for cardiovascular mortality associated with HRT non-
compliance. Incorporating these effects limits overestimating the number of QALYs acquired 
through surgical prevention, which in turn minimizes underestimating the final baseline 
ICER/QALY. The one-way sensitivity and PSA show that the model is robust to the various 
parameter estimates. The confidence-intervals or range of these estimates are reasonably 
wide. Costs of surgical prevention or treatment costs for OC, BC, or cardiovascular events do 
not significantly impact model results.  
There are also limitations of this model. As far as possible, population-based data have been 
used to obtain the parameters in the analysis. However, primary data for the BRCA mutation 
prevalence in FH-negative SJ women are unavailable and this has been calculated by using a 
combination of other parameters, such as the overall BRCA mutation prevalence in SJ 
women, BRCA mutation prevalence in FH-positive individuals and the probability of having a 
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positive FH fulfilling the genetic testing criteria (Table-1).  But the three probabilities used to 
calculate this value have been determined from population-based data and the value used 
in the analysis (0.000493) is realistic and similar to estimates expected from a low-risk 
general population.46 Additionally, sensitivity analysis has found population-testing to still 
be cost-effective despite the significant uncertainty around this parameter. We have not 
included the benefit of Tamoxifen based chemoprevention reported in high-risk women. 
Tamoxifen prevents mainly estrogen receptor positive BC and ~70% off BRCA1-associated 
BC are ER negative.47, 48 Besides overall uptake rates reported in the literature are low 
(~16%)49 and unknown for the SJ population. Including Tamoxifen would make the model 
more cost-effective and we chose not to overestimate its benefit given that tamoxifen has 
not been shown to reduce incidence of ER negative BC.  Our analysis covers testing for the 
BRCA1 founder mutation which is common in SJ. Women with very strong FH of cancer 
(similar to that found in the non-Jewish general population) who test negative for the SJ 
founder mutation should be referred to clinical genetics for a full/extended BRCA1/BRCA2 
screen analysis for non-founder mutations.  
The different scenarios tested by the model add to the strength of the analyses. The risk of 
CHD from undertaking a RRSO has been incorporated in the model assuming an 80% HRT 
compliance, yet the true compliance rate in a SJ population has not been fully determined. 
This is important as HRT alleviates cardiovascular risk and the cardiovascular mortality 
impact is seen predominantly in those who are non-compliant.14 However, HRT compliance 
does not seem to have a major impact on the overall results, as population-testing remains 
highly cost-effective even at 0% compliance rate in our scenario analysis. Our analysis does 
not include the excess mortality due to lung/colorectal cancer reported in the Nurses Health 
Study, as it may be confounded by cigarette smoking or other risk related behaviours and 
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this finding has not been corroborated in some other larger studies.  Smoking itself is 
associated with early menopause.50, 51 Additionally, results of the NIH-AARP (American 
Association of Retired Persons) Diet-&-Health Study in 185,017 women, found stratification 
by smoking status, demonstrated that increased lung cancer risk associated with bilateral 
oophorectomy was absent in non-smokers and restricted only to smokers.50 Additionally, 
the European Prospective Investigation into Cancer and Nutrition (EPIC) study (337,802 
women) results found no significant association between colorectal cancer risk and age at 
menarche/menopause or type of menopause (surgical/natural).52 Nevertheless, we 
modelled a scenario of increased all-cause mortality (NNH of 1 in 8) reported by Parker et 
al,14 and found that population testing in SJ remains cost-effective (ICER=£67/QALY or 
$308/QALY).  Whether pre-menopausal oophorectomy leads to a reduction in BC-risk has 
recently been the subject of recent debate. Although a recent Dutch paper found no such 
benefit,41other investigators have reported BC-risk reduction with pre-menopausal 
oophorectomy.53-55 Given the recent uncertainty around this parameter, if we assume no 
benefit from pre-menopausal oophorectomy then the ICER increases, but the value is still 
well below the NICE and USA WTP thresholds indicating that population based testing is still 
cost effective. Specific uptake rates of RRM and RRSO in SJ women are lacking. In the 
absence of these data, we use RRM and RRSO rate data from UK BRCA1 carriers. It is 
reassuring that population testing remains cost-effective even at lower uptake rates of 13% 
for RRM and 49% for RRSO (ICER= £67.81/QALY and $312.84/QALY) reported in Israeli 
women compared to women from western populations.42  
The Jewish population is the first population in whom unselected population-based BRCA-
testing has been extensively evaluated and can become a reality. Overall this does not harm 
psychological well-being or quality of life.2 Our study shows population testing for BRCA1 
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mutations in SJ is extremely cost-effective compared to traditional FH-based testing and 
supports a paradigm change to population-based testing in the SJ population. This 
corroborates initial results from the AJ population,3, 45  providing the rationale for offering 
BRCA founder-mutation testing in the entire Jewish population. This could have implications 
for BRCA-testing in other founder populations too. The number of cases of BC and OC are 
expected to increase by 24% and 27% in the UK, by 34% and 39% in the USA, by 51% and 
55% in Israel and by 55% and 55% worldwide by 2035.56 Identification of high-risk 
individuals who can benefit from effective preventive interventions provides an excellent 
opportunity to reduce the burden of BC and OC. It is extremely important that we utilize this 
opportunity offered by a population testing strategy for maximizing cancer prevention. 
Delivering such a strategy will warrant broadening of existing, and development of new 
referral and management pathways. These will differ from one country to another. There is 
also the need to increase public and health professional awareness and knowledge; as well 
as develop closer coordination and better communication between general practitioners, 
hospital health professionals, stakeholder and professional organizations, community 
charities and public at large. 
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Table-1: Probabilities used in the Markov Model 
Probability Value (95% confidence 
interval) 
[Range] 
Description Source 
P1 0.007049 (0.0028 – 0.0145)  BRCA1 mutation prevalence in  
Sephardi population  
Barsade8 
P2 0.60 (0.47 – 0.74) Probability that BRCA1 carrier 
will undergo RRM 
Evans57 
P3 0.85 (0.44 – 0.96) Reduction in risk of ovarian 
cancer from RRSO 
Kauff54 
P4 0.40 (0.35 – 0.46) Probability that BRCA1 carrier 
without RRSO will get ovarian 
cancer 
Chen12 
P5 0.0185 (0.0005 – 
0.09898) 
Probability that a non-carrier 
will get ovarian cancer 
CRUK58 
0.0128 (0.0126 – 0.013) Probability that a non-carrier 
will get ovarian cancer – US 
estimate 
SEER59 
P6 0.1238 (0.1043 – 0.1454) Probability of having a positive 
family history fulfilling genetic 
testing clinical criteria 
Manchanda3 
P7 0.053 (0.0199 – 0.113) BRCA1 mutation prevalence in 
FH positive individuals 
Barsade8 
P8 0.000493 [0.000345 – 
0.000641] 
BRCA1 prevalence in family 
history negative individuals  
 
P9 0.91 (0.62 – 0.98) Reduction in breast cancer risk 
from RRM without RRSO in 
BRCA1 carriers  
Rebbeck13 
P10 0.57 (0.47 – 0.66) Probability that BRCA1 carrier 
without RRM will get breast 
cancer 
Chen12 
P11 0.129 (0.11 – 0.14) Probability that a non-carrier 
will get breast cancer  
CRUK58 
0.1243 (0.1236 – 0.1249) Probability that a non-carrier 
will get breast cancer – US 
estimate 
SEER23 
P12 0.66 (0.53 – 0.80) Probability that a BRCA1 carrier 
will follow-up with RRSO 
Evans57 
P13 0.47 (0.35 – 0.64) Reduction in risk of breast 
cancer from RRSO alone in 
BRCA1 carrier 
Rebbeck60 
P14 0.95 (0.78 – 0.99) Reduction in risk of breast 
cancer from RRM with RRSO in 
BRCA1 carrier 
Rebbeck13 
P15 0.0303 (0.011 – 0.043) Risk of mortality from CHD after Parker14 
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RRSO 
P16 0.8008 (0.25 – 0.83) Compliance with HRT Read16 
Garcia61 
CRUK – Cancer Research United Kingdom, CHD – coronary heart disease, FH – family history, 
HRT – Hormone replacement therapy, RRM – risk reducing mastectomy, RRSO – risk 
reducing salpingo-oophorectomy, SEER – Surveillance, Epidemiology, and End Results 
Program, SJ – Sephardi Jewish 
P1: The probability of carrying a BRCA founder mutation in an unselected SJ population is 
calculated from analysis carried out by Bar-sade.8. The estimate was calculated by dividing 
the number of 185delAG BRCA1 mutations detected in the Iraqi and Moroccan Jews by the 
total number of samples taken from those two countries=7/993. 
 
P2: The probability of RRM uptake for a BRCA1 carrier is taken from Evans et al, 2009.57 
 
P3: The reduction in ovarian cancer risk in BRCA1 carriers is obtained from Kauff et al 2008, 
whose findings are consistent with other studies reporting that following an RRSO, a 4% risk 
of peritoneal cancer remains.54 
 
P4: The probability that a BRCA1 carrier without RRSO will get ovarian cancer is taken from 
Chen et al, 2007.12 
 
P5: Estimates for of risk of ovarian cancer in non-BRCA UK carriers is obtained from Cancer 
Research UK58 and from SEER data59 for US carriers. 
 
P6: GCaPPS study provides the estimates for probability of having a positive family history 
fulfilling current clinical criteria for genetic testing in a Jewish population.3  
 
P7: BRCA1 mutation prevalence in FH positive individuals is obtained from Bar-sade et al, 
19988 : 6 carriers detected in 112 Sephardi individuals with of breast or ovarian cases, giving 
a probability of (6/112) 0.053. 
 
P8: BRCA1 prevalence in family history negative individuals is obtained by multiplying the 
probability of having a strong FH fulfilling current clinical criteria for genetic testing (P6) by 
the BRCA1 mutation prevalence in FH positive individuals (P7). This value was then taken 
away from the BRCA1 mutation prevalence in  general population controls (P1) to get the 
BRCA1 Mutation prevalence in FH negative individuals (P8): 0.007049 – (0.123 * 0.053). 
 
P9:   Reduction in breast cancer risk from RRM in BRCA1 carriers is obtained from PROSE 
study data reported by Rebbeck et al, 2004.13  
 
P10: The probability that BRCA1 carrier without RRM will get breast cancer is obtained from 
a meta-analysis conducted by Chen et al, 2007 12  
 
P11: Estimates for risk of breast cancer in UK non-BRCA carriers is taken from the UK Office 
for National Statistics and from Cancer Research UK58 and from SEER data59 for US women. 
 
P12: Probability of a BRCA1 carrier undergoing an RRSO are taken from Evans et al, 2009.57 
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P13: Reduction in risk of breast cancer from RRSO alone in a BRCA1 carrier is obtained from 
a meta-analysis by Rebbeck et al, 2009.60 
 
P14: Reduction in risk of breast cancer in BRCA1 carriers undergoing RRM and RRSO is 
obtained from data from the PROSE study by Rebbeck et al, 2004.13 
 
P15: Risk of mortality from CHD after RRSO is taken from the Nurses Health Study. 14 This is 
reported as 0.0303 pre-menopausal women not taking HRT but undergoing a RRSO. 
 
P16: Compliance rate for HRT is taken from Read et al, 201016 and the lower limit of the 
range modelled is from Garcia 2015.61 
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Table 2: UK and US costs used in the Markov Model 
Item UK cost (£) US cost ($) Source 
Cost of genetic testing for 
BRCA1 founder mutation 50 300 
GCaPPS2 
Cost of counselling with 
DVD 26 41 
GCaPPS,2 PSSRU Unit costs of Health 
and Social Care,20 Schwartz62 
Cost of RRSO (and HRT 
and osteoporosis 
prevention) 
2772 8144 
NHS Reference costs,19 BNF,63 
Grann,36, Williams-Frame64 
Cost of ovarian cancer 
diagnosis and treatment 14,201 127,995 
NHS Reference costs,19 NICE 
guideline,65 Grann36 
Yearly cost of ovarian 
cancer treatment year 1-2 5169 14,071 
NHS Reference costs,19 NICE 
guideline,65 CRUK,66 Grann36 
Yearly cost of ovarian 
cancer treatment year 3-5 4798 14,071 
NHS Reference costs,19 NICE 
guideline65 CRUK,66 Grann36 
Terminal care cost with 
ovarian cancer 15588 89,424 
National Audit Office,67 36 
Cost of risk reducing 
mastectomy 4058 12,596 
NHS reference cost,19 weighted for 
21% complication rate,68 Grann36 
Cost of breast screening 50 153 Robertson 2011,
69 NHS Reference 
costs,19 Grann36 
Cost of breast screening 
genetic 50 - 214 
153 – 
1603 
NHS Reference costs19, NICE 
guideline,70 Grann36 
Cost of breast cancer 
diagnosis and treatment 
in non-BRCA carriers 
15,993 82,030 
NHS Reference costs19, NICE 
guideline71, NICE guideline,32 Grann36 
Cost of breast cancer 
diagnosis and treatment 
in BRCA1 carriers 
14,476 75,873 
NHS Reference costs19, NICE 
guideline71, NICE guideline,32 Grann36 
Yearly cost of breast 
cancer treatment for 5 
years 
1852 7738 
NHS Reference costs19, Robertson 
201169, BNF63, NICE guideline71, NICE 
guideline,32 Grann36 
Yearly cost of genetic 
breast cancer for 5 years 1746 7738 
NHS Reference costs19, Robertson 
201169, BNF63, NICE guideline71, NICE 
guideline,32 Grann36 
Terminal care cost with 
breast cancer 15,588 65,403 
National Audit Office,67 Grann36 
Cost of coronary heart 
disease 3343 23,012 
NHS Reference costs,19 Afana72 
BNF – British National Formulary, GCaPPS – Genetics Cancer Prediction through Population 
Screening study, HRT – hormone replacement therapy, NHS – National Health Service, NICE 
– National Institute for Health and Clinical Excellence, PSSRU – Personal Social Services 
Research Unit, RRSO – risk reducing salpingo-oophorectomy, RRM – risk reducing 
mastectomy. Model costs are estimated at 2015 prices 
RRSO costs: Calculated using national reference costs for upper genital tract 
laparoscopic/endoscopic intermediate procedure. RRSO costs include HRT costs taken from 
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the BNF63, until the average age of menopause at 51 years with an 80% compliance rate 
assumed. Bone health monitoring and osteo-protection costs are comprised of three follow up dual 
energy X-ray absorptiometry (DEXA) scans and daily calcium and vitamin-D3 supplementation for 
osteo-protection.19 Prophylactic salpingo-oophorectomy costs in the US population are taken 
from Grann et al, 201136 and inflated to 2015 prices using the medical component of the US 
consumer price index. 
 
Ovarian cancer costs: Diagnosis costs include pelvic exam, ultrasound, percutaneous biopsy 
and cytology, CT scan and CA125 test. Treatment costs include surgical costs for a lower and 
upper genital tract procedure with 6 chemotherapy cycles of carboplatin and paclitaxel and 
chemotherapy administration costs. Follow-up costs include consultant visits, CT scan and 
CA125 tests and recurrent ovarian cancer treatment costs.19, 65 UK costs are taken from NICE 
guideline and NHS reference costs.19, 65 Ovarian cancer costs for the US population are taken 
from Grann et al, 201136 and inflated to 2015 prices using the medical component of the US 
consumer price index. 
 
Breast cancer screening for non-BRCA carriers: follows the UK NHS breast cancer screening 
program where mammography is offered every 3 years from the age of 50 until 70.73  For 
the US, recommendations in a CDC report were followed where mammography is offered 
every 2 years from the age of 50 until 70.74 
 
Breast cancer screening for BRCA1 carriers: follows NICE guideline on familial breast cancer 
where annual MRI is offered from the age of 30 to 49. Annual mammogram is offered from 
the age of 40 to 69.70 For the US, recommendations in a CDC report were followed where 
MRI and mammography are offered annually from the age of 30 until 50. Mammography is 
then offered annually from the age of 50 until 70.74 UK costs are obtained from NHS 
reference costs.19 US costs of mammography and MRI are taken from Grann et al, 201136 
and inflated to 2015 prices using the medical component of the US consumer price index. 
 
RRM costs are weighted for a 21% complication rate 68, 75and obtained from NHS reference 
costs19. Cost of RRM is taken from Grann et al, 201136 and inflated to 2015 prices using the 
medical component of the US consumer price index. 
 
Breast cancer treatment: costs include mammogram, ultrasound, clinical examination 
biopsy71 and sentinel lymph node biopsy and axillary lymph node dissection. 76 Differences 
in non-BRCA and BRCA cancer treatment costs arise from the proportion of cancers that are 
non-invasive DCIS and invasive. In non-BRCA populations, 10% breast cancer is non-invasive 
DCIS and 90% breast cancer is invasive.76-79 In BRCA populations 20% of cancers are DCIS 
and 80% invasive.68, 80 Costs include costs of breast conserving surgery, radiotherapy,71 
chemotherapy, endocrine therapy,32, 71 and bisphosphonate costs63 and trastuzumab costs 
for HER2 positive breast cancer.76 Follow-up costs and treatment of relapse/ recurrence are 
included.81-83 Cost of breast cancer treatment is taken from Grann et al, 2011 and inflated to 
2015 prices using the medical component of the US consumer price index.36 
 
Terminal cancer costs: End of life care costs for breast and ovarian cancer are obtained form 
end of life care report submitted to the National Audit Office, UK67 and from Grann et al, 
2011 for the US population and inflated to 2015 prices using the medical component of the 
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US consumer price index.36  
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Table-3: Model outcomes for Population testing and Family-history based strategies  
Strategy Cost (£) Life years* QALYs Cost ($) 
Life 
years* QALYs 
Clinical criteria/ Family 
history based testing 1647.53 47.0416 22.4220 5972.93 45.7200 22.1224 
Population based testing  1714.61 48.0432 23.4226 6281.38 46.7205 23.1224 
ICER/QALY  67.04   308.42   
 
QALY – Quality Adjusted Life Years, ICER – Incremental Cost-effectiveness Ratio 
*Undiscounted values shown for life years. Costs and QALYs are discounted.  
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Figure-1: Markov model structure 
 
Schematic diagram showing the Markov model structure for population and clinical criteria/family 
history (FH) based testing for BRCA mutations. In the population testing arm, all Sephardi Jewish (SJ) 
women ≥ 30 years old are offered BRCA1 founder mutation testing. If SJ women test BRCA1 positive 
they are then offered a risk reducing mastectomy (RRM) and risk reducing salpingo-oophorectomy 
(RRSO). Depending on the probability of women undertaking a RRM and/or RRSO they are placed 
into different health states and then progress to either BRCA1 associated breast cancer (BC) or 
ovarian cancer (OC). In the FH arm, only women who have positive FH criteria matching the current 
guidelines on genetic testing are offered a genetic test. They then follow the same pathway as 
women in the population testing. Women with a negative FH are either BRCA1 negative or have an 
undetected BRCA1 mutation. BRCA1 negative women progress to sporadic non-BRCA OC or non-
BRCA BC. Undetected BRCA1 SJ women progress to BRCA1 associated BC or BRCA1 associated OC. All 
women undergoing an RRSO have an increased risk of fatal coronary heart disease (CHD). Although 
not shown in the figure, background mortality has been modelled for all health states. Progression 
through the model is dependent on the probabilities presented in Table 1. 
 
BC- Breast Cancer; CHD- Coronary heart disease; FH – Family history OC-Ovarian Cancer; RRM – Risk 
reducing mastectomy; RRSO –Risk reducing salpingo-oophorectomy 
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Figure-2: One-way sensitivity analysis for top 6 parameters affecting UK incremental cost-
effectiveness ratio (ICER) 
One-way sensitivity analysis in the form of a tornado diagram for the top 6 parameters that have the 
largest impact on the incremental cost-effectiveness ratio (ICER) of population based testing for 
BRCA1 founder mutations, compared to a family history (FH) based approach in the UK.   
Y-axis: top 6 parameters with greatest impact on ICER. X-axis: ICER per quality adjusted life year 
(QALY) (discounted) calculated through varying probabilities and utilities by its upper and lower 95% 
confidence interval or range as described in Table-1. Costs were varied by +/- 30%. The ‘minimum 
value’ represents the lower and the ‘maximum value’ represents the upper limit of the parameter. 
34 
 
Figure-3: One-way sensitivity analysis for top 6 parameters affecting US incremental cost-
effectiveness ratio (ICER) 
One-way sensitivity analysis in the form of a tornado diagram for the top 6 parameters that have the 
largest impact on the incremental cost-effectiveness ratio (ICER) of population based testing for 
BRCA1 founder mutations, compared to a family history (FH) based approach in the US.   
Y-axis: top 6 parameters with greatest impact on ICER. X-axis: ICER per quality adjusted life year 
(QALY) (discounted) calculated through varying probabilities and utilities by its upper and lower 95% 
confidence interval or range as described in Table-1. Costs were varied by +/- 30%. The ‘minimum 
value’ represents the lower and the ‘maximum value’ represents the upper limit of the parameter. 
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Figure-4: UK Probabilistic Sensitivity Analysis for Sephardi Jewish population 
 
Probabilistic sensitivity analysis showing the percentage of iterations that are cost-effective in the 
UK at different willingness to pay (WTP) thresholds per quality adjusted life year (QALY) when model 
parameters are varied simultaneously based on their distributions.  
The Y axis represents 10,000 iterations plotted on a cost-effectiveness acceptability curve (CEAC) 
presenting the proportion of simulations that are cost-effective. The X axis shows the willingness to 
pay thresholds/QALY. The square marked line shows the CEAC for the family history arm whilst the 
triangle marked line shows the CEAC for the population testing arm.   
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Figure-5: US Probabilistic Sensitivity Analysis for Sephardi Jewish population 
 
Probabilistic sensitivity analysis showing the percentage of iterations that are cost-effective in the 
USA at different willingness to pay (WTP) thresholds per quality adjusted life year (QALY) when 
model parameters are varied simultaneously based on their distributions.  
The Y axis represents 10,000 iterations plotted on a cost-effectiveness acceptability curve (CEAC) 
presenting the proportion of simulations that are cost-effective. The X axis shows the willingness to 
pay thresholds/QALY. The square marked line shows the CEAC for the family history arm whilst the 
triangle marked line shows the CEAC for the population testing arm.   
 
